text_1: Pioglitazone use is not associated with an increased risk of prostate cancer.
text_2: RESULTS Among 193,099 persons in the bladder cancer cohort, 34,181 (18%) received pioglitazone (median duration, 2.8 years; range, 0.2-13.2 years) and 1261 had incident bladder cancer.